Study title: Effects of tamoxifen on lipid profile and coagulation parameters in male patients with pubertal gynecomastia. Novoa FJ, Boronat M, Carrillo A, Tapia M, Diaz CJ, Chirino R. Hormone Research 2002;57(5-6):187-91 2002;(5-6):187-191.Effects of tamoxifen on lipid profile and coagulation parameters in male patients with pubertal gynecomastia. Novoa FJ, Boronat M, Carrillo A, Tapia M, Diaz CJ, Chirino R. Hormone Research 2002;57(5-6):187-91 2002;(5-6):187-191.
| Type of medicine: Medicines containing chemical active substances | |||||
| Therapeutic area: Neoplasms [C04] | |||||
| Brands: Please see report | |||||
| MAH holders: Please see report | |||||
| Assessment: | |||||
| Active substance: TAMOXIFEN | |||||
| ATC code: L02BA01 | |||||
| Document link: | |||||
| Document date: | |||||
| Study number: | |||||
| EudraCT number: | |||||
| Scope of study: Clinical | |||||
| Population of study subjects: | Preterm newborn Infants | Newborn infants (1 to 27 days) | Infants and toddlers (28 days to 24 months) | Children (2 to 11 years) | Adolescents (12 to 18 years) |
| - | - | - | - | - | |